Eltrombopag Induced Liver Dysfunction During Treatment of Immunethrombocytopenic Purpura

N/ARecruitingNCT07093606

Sohag University100 enrolled

Overview

this study amis to assess the incidence and severity of liver dysfunction in ITP patients receiving eltrombopag.

Study Type

INTERVENTIONAL

Allocation

Purpose

OTHER

Masking

NONE

Enrollment

100

Conditions

ITP - Immune Thrombocytopenia

Interventions

EltrombopagDRUG

ITP patients will receive Eltrombopag and evulate occurance of liver disordres .

Eligibility

Sex: ALLMin age: 18 YearsMax age: 75 Years

Medical Language ↔ Plain English

Inclusion Criteria Adult patients (≥18 years) diagnosed with primary ITP. Receiving eltrombopag as part of their treatment. Baseline liver function tests (LFTs) within normal limits. Patients with diabetes Patients without diabetes Patients with fatty liver Patients without fatty liver Exclusion Criteria: Pre-existing liver disease (e.g., hepatitis, cirrhosis, NAFLD). Concurrent use of hepatotoxic drugs. Patients lost to follow-up.

Locations (1)

Sohag university hospital

Sohag, Egypt

RECRUITING

Outcomes

Primary Outcomes

•To assess the incidence and severity of liver dysfunction in ITP patients receiving eltrombopag.

the incidence and severity of liver dysfunction in ITP patients

Time frame: 3-6 months after receiving eltombopag

Central Contacts

Peter A Alfy, Resident

CONTACT

01274069691 peter.adel.dola@gmail.com

Usama M Abdelaal, Professor

CONTACT

01065962094

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.